Remus Pharmaceuticals MD, chairman and AGM

Remus Pharmaceuticals board of directors

At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares

An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.

Statutory auditor

Named in the results for the quarter to Mar 2026.

M/s Pankaj R. Shah and AssociatesPeer-review certificate valid to Oct 2027

A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.

Remus Pharmaceuticals AGM and shareholder votes

Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Remus Pharmaceuticals dividend history

Postal ballot, 6 Oct 2026

2,189 shareholders on the register on 28 Aug 2026; votes counted by TAPAN SHAH / TAPAN SHAH.The company's voting result (opens in a new tab)

To Approve the Migration of Listing/Trading of Equity Shares of the Company from Emerge Platform of National Stock Exchange of India Limited ('NSE Emerge') to Main Board of National Stock Exchange of India Limited ('NSE') and Main Board of BSE Limited ("BSE")MoreLess
SpecialPromoters have an interest in it
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 2.02% · promoters 0.00% · institutions 2.48% · other public 7.96%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 29 Sep 2026, 4 resolutions

2,138 shareholders on the register on 22 Sep 2026; present: 4 promoters and 20 others; votes counted by TAPAN SHAH / TAPAN SHAH & COMPANY SECRETARIES.The company's voting result (opens in a new tab)

To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, together with the Reports of the Board of Directors and the Auditors thereonMoreLess
Ordinary
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 70.95% · promoters 98.28% · institutions 0.00% · other public 5.17%
To declare dividend of Rs. 0.50 (5%) per equity share of Rs. 10/- (Rupees Ten only) each for the Financial Year ended on March 31, 2026
Ordinary
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 70.95% · promoters 98.28% · institutions 0.00% · other public 5.17%
To appoint Mrs. Anar Swapnil Shah (DIN: 06895297) as a director, liable to retire by rotation who has offered herself for re-appointment
OrdinaryPromoters have an interest in it
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.14%
Turnout: all 36.08% · promoters 49.14% · institutions 0.00% · other public 5.17%
Appointment of Mr. Ashutosh Naginbhai Valani (DIN: 00559688) as a Non-Executive Independent Director of the Company for a term of 5 (Five) Consecutive Years
Ordinary
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.14%
Turnout: all 70.95% · promoters 98.28% · institutions 0.00% · other public 5.17%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Dealings with its subsidiaries, promoters, directors and their firms, reported every half-year.Promoters and their stake

Half-year to Mar 2026: ₹35.4 Cr30 dealings
Half-year to Sep 2025: ₹77.8 Cr26 dealings
Half-year to Mar 2025: ₹56.2 Cr30 dealings

Between	Dealing
Espee Global Holdoing LLC and RISE PHARMA LLCEntities where KMPs are having significant influence	Sale of goods or services	14.46	45.58	11.23
Remus Pharmaceuticals Ltd and Ratnatris Pharmaceuticals Private LimitedEntities where KMPs are having significant influence	Purchase of goods or services	4.36	1.15	3.02
Espee Global Holdoing LLC and ESPEE THERAPEUTICS LLPEntities where KMPs are having significant influence	Purchase of goods or services	3.56	0.00	−1.61
Espee Global Holdoing LLC and RENOSEN PHARMACEUTICALS PVT LTDEntities where KMPs are having significant influence	Purchase of goods or services	2.01	0.00	0.00
Espee Global Holdoing LLC and SHASHIN SHAHKey Management Personnel	Purchase of goods or services	1.80	0.00	0.00
Remus Pharmaceuticals Ltd and Senores Pharmaceuticals LimitedEntities where KMPs are having significant influence	Purchase of goods or services	1.24	1.42	0.80
Espee Global Holdoing LLC and RISE PHARMA LLCEntities where KMPs are having significant influence	Purchase of goods or services	1.22	45.58	3.86
Remus Pharmaceuticals Ltd and Arpit ShahKey Management Personnel	Remuneration	1.17	0.00	0.00
Remus Pharmaceuticals Ltd and Renosen Pharmaceuticals Private LimitedEntities where KMPs are having significant influence	Purchase of goods or services	1.11	0.00	0.20
Remus Pharmaceuticals Ltd and Senores Pharmaceuticals LimitedEntities where KMPs are having significant influence	Sale of goods or services	1.04	0.00	0.00
Remus Pharmaceuticals Ltd and Roma ShahKey Management Personnel	Remuneration	0.62	0.00	0.00
Remus Pharmaceuticals Ltd and Ratnatris Pharmaceuticals Private LimitedEntities where KMPs are having significant influence	Purchase of goods or services	0.56	1.15	3.02
Remus Pharmaceuticals Ltd and Senores Pharmaceuticals LimitedEntities where KMPs are having significant influence	Any other transactionReimbursement of Expenses (Excluding Taxes)	0.47	1.42	0.80
Remus Pharmaceuticals Ltd and Swapnil ShahKey Management Personnel	Remuneration	0.35	0.00	0.00
Remus Pharmaceuticals Ltd and Ratnatris Pharmaceuticals Private LimitedEntities where KMPs are having significant influence	Interest received	0.23	4.71	4.99
Relius Pharma S.R.L and Andres Leonardo Ramos AliagaKey Management Personnel	Remuneration	0.21	0.02	0.05
Remus Pharmaceuticals Ltd and Senores FoundationEntities where KMPs are having significant influence	Any other transactionCSR Contribution	0.20	0.00	0.00
Remus Pharmaceuticals Ltd and Aelius Projects LLPEntities where KMPs are having significant influence	Any other transactionRent Expense	0.19	0.01	0.00
Espee Global Clinical Trial Services pvt ltd and Ajitpal SinghKey Management Personnel	Remuneration	0.17	0.00	0.03
Remus Pharmaceuticals Ltd and Ratnatris Pharmaceuticals Private LimitedEntities where KMPs are having significant influence	Sale of goods or services	0.14	1.15	0.90
Remus Pharmaceuticals Ltd and Anar ShahKey Management Personnel	Remuneration	0.11	0.00	0.00
Remus Pharmaceuticals Ltd and Senores Pharmaceuticals LimitedEntities where KMPs are having significant influence	Interest received	0.07	1.56	1.63
Espee Global Clinical Trial Services pvt ltd and ESPEE THERAPEUTICS LLPEntities where KMPs are having significant influence	Any other transactionReimbursement of Expenses (Excluding Taxes)	0.04	0.00	0.01
Espee Global Clinical Trial Services pvt ltd and Aelius Projects LLPEntities where KMPs are having significant influence	Any other transactionRent Expense	0.01	0.00	0.00
Remus Pharmaceuticals Ltd and Balwant PurohitKey Management Personnel	Any other transactionDirector's Sitting Fees	0.01	0.00	0.00

The 25 largest of 30 dealings in the half-year to Mar 2026, ₹ crore.

Fines

Reported in the filing for the quarter to Jun 2026.

Fine or penaltyMinistry of Labour - BoliviaSince 27 Apr 2026
Imposed a penalty of 4000 Bolivian Boliviano for non-complaince with Labour Laws as per the Ministry of Labour - Bolivia
Fine imposed by Ministry of Labour for 4 infraction

In the company's own words, from its latest governance filing.

Investor complaints and compliance

Quarter by quarter.

Investor complaints received and resolved, the company's own count

Received
Resolved

Open at the quarter's end

None open at any quarter's end.

The filing has a part on fines and penalties: Yes
The filing has a part on tax disputes: No

The company's own answers in its filing.

How money raised was used

Reported for the quarter to Mar 2025. The company's results filing for the quarter to Mar 2026 says no statement of how money raised was used applies to it.

Raised	Amount raised	For	Set aside	Spent	Spent elsewhere	Reason and comments
Public IssuesMay 2023	47.68		–	–	No	Auditors: Nona

₹ crore. Checked by is the agency appointed to monitor how the money is used. The reason and the comments are the company's, its audit committee's and its auditors' own words.